Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction Are Independent From its Diuretic and Potassium-Sparing Effects

The Metabolic Effects of Mineralocorticoid Receptor Antagonists in Heart Failure Patients

Heart failure (HF) remains a leading cause of cardiovascular morbidity and mortality worldwide. Mineralocorticod receptor (MR) antagonists (spironolactone and eplerenone) have been studied in HF patients and in patients with acute coronary syndrome or post-myocardial infarction and left ventricular (LV) dysfunction, as well as hypertensive subjects without HF symptoms. It has suggested that min...

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

BACKGROUND Aldosterone blockade is recommended for patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction; however, the perceived risk of hyperkalemia may limit implementation of this therapeutic approach. This subanalysis examined the relationship between eplerenone, serum potassium (K(+)), and clinical outcomes in the Eple...

Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction

INTRODUCTION Heart failure is a frequent complication after acute myocardial infarction (MI) and carries a poor prognosis. Current treatments inhibit the renin-angiotensin-aldosterone system but suppression of aldosterone may be incomplete. The aldosterone antagonist spironolactone has been shown to improve survival in patients with chronic, severe heart failure. Eplerenone is a selective aldos...

Heart Failure Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study

Eplerenone in patients with acute myocardial infarction complicated by heart failure.

Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure To the Editor: Pitt et al1 have concluded in their study that eplerenone should be prescribed to all of the postacute myocardial infarction patients with reduced left ventricular ejection fraction and heart failure. However, there are a few concerns in using eplerenone in certain populations. During the develop...